Nodus Oncology attended the EORTC-NCI-AACR Symposium in Barcelona and were proud to present their most recent data on the development of a novel, potent PARG inhibitor NODX-010, made in partnership with the Lead Discovery Center. Displaying favourable PK and in vivo target engagement, the NODX-010 compound demonstrated tumour regression in a mouse model of breast cancer.
View or download the full poster here.